Table 1.
Prediction performance and effect size of the association of C-reactive protein and IMDC risk tool with overall survival and progression-free survival for patients treated with atezolizumab plus bevacizumab.
| Overall survival | Progression free survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | HR | 95% CI | p-value | c | n | HR | 95% CI | p-value | c | |
| Log C-reactive protein (mg/L) | 527 | 1.71 | 1.54–1.90 | <0.001 | 0.76 | 527 | 1.27 | 1.18–1.35 | <0.001 | 0.62 |
| IMDC risk group | 552 | <0.001 | 0.67 | 552 | <0.001 | 0.59 | ||||
| Favorable | 1.00 | 1.00 | ||||||||
| Intermediate | 2.90 | 1.73–4.86 | 1.44 | 1.11–1.88 | ||||||
| Poor | 8.35 | 4.75–14.7 | 2.68 | 1.91–3.77 | ||||||
| Log hemoglobin (g/L) | 547 | 0.05 | 0.02–0.14 | <0.001 | 0.67 | 547 | 0.26 | 0.12–0.55 | <0.001 | 0.6 |
| Log neutrophils (10^9/L) | 543 | 3.38 | 2.22–5.14 | <0.001 | 0.64 | 543 | 1.87 | 1.41–2.49 | <0.001 | 0.57 |
| ECOG PS | 550 | 1.89 | 1.46–2.44 | <0.001 | 0.63 | 550 | 1.16 | 0.98–1.38 | 0.090 | 0.53 |
| Log platelets (10^9/L) | 547 | 3.11 | 2.02–4.80 | <0.001 | 0.62 | 547 | 2.11 | 1.56–2.84 | <0.001 | 0.59 |
| Log calcium, corrected (mmol/L) | 441 | 0.94 | 0.40–2.18 | 0.881 | 0.4 | 441 | 1.12 | 0.59–2.12 | 0.735 | 0.56 |
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival; IMDC, International Metastatic renal cell carcinoma Database Consortium; n, number of patients; ECOG PS, Eastern Cooperative Oncology Group Performance Status.